Lead-Discovery-Center

>> Press release archive



Sign up to our newsletter
Stay up-to-date on all our news and activities

press releases

12.09.2019

Investment Plan for Europe – Successful launch of Tech Transfer Fund “KHAN-I”

Khanu Management GmbH (Khanu), a drug discovery focused fund management team, announces the successful launch of KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I), based in Dortmund, Germany.
The European Investment Fund (EIF, Luxemburg), the Austria Wirtschaftsservice GmbH (Vienna, Austria) and the Max Planck Foundation (Munich, Germany) committed in a first closing an investment of a total volume of € 60 million into KHAN-I for a period of 5 plus 2 years in early-stage drug discovery projects. The Khanu fund management team will invest a minority amount.

>> Continue >> download PDF

 

12.04.2019

A PhD’s guide on how to organize a conference

Eleven Early Stage Researchers from eight different institutions including the LDC, all part of the EU DivIDE network, tell us about their experience organizing their first international conference – and what they learned on the way.

>> Continue

>> click here

 

10.04.2019

Bekämpfung resistenter Bakterien: Bundesministerium für Bildung und Forschung fördert NRW Konsortium NanoComBac mit zwei Millionen Euro

 

Die Lead Discovery Center GmbH (LDC) ist Teil des neuen, geförderten NRW Konsortiums NanoComBac, das sich der Entwicklung neuer antibiotischer Therapiemöglichkeiten gegen resistente Bakterien widmet.

>> Continue

 

02.04.2019

LDC and Korean Drug Development Fund collaborate to mature innovative drug discovery projects in South Korea

Seoul, South Korea. The Lead Discovery Center (LDC) and the Korean Drug Development Fund (KDDF) have entered into an agreement to facilitate the interaction between LDC and the prospering South Korean biotech scene.

>> Continue >> download PDF

 

29.03.2019

LDC Receives the City of Dortmund Business Award

The Lead Discovery Center (LDC) has won Dortmund’s Business Prize, awarded yearly by the Wirtschaftsförderung and the Sparkasse Dortmund. The distinguished jury selected the LDC for its innovative business concept and its outstanding achievements for the benefit of society. The company forms a vital link between academia and industry. In close collaboration with both partners, it helps transform great ideas into medicines that can change the lives of millions of people.

>> Continue >> download PDF

 

19.02.2019

New Center of Competence for Innovative Diabetes Therapy (KomIT) is funded by NRW and EU

 

The Lead Discovery Center (LDC) is part of a new consortium of eight partners from industry and academia focusing on the development of new diabetes therapies.

 

 

 

>> Continue

 

08.01.2019

LDC and European-Canadian Consortium Attract €1.1 Million to Develop new Therapies Against Rare Disease ATD

 

The Lead Discovery Center (LDC) has teamed up with McGill University in Canada, Institut National de la Santé Et de la Recherche Médicale (INSERM) in France and Semmelweis University in Hungary to discover new approaches for the treatment of alpha-1 antitrypsin deficiency (ATD), a rare genetic disorder that lead to severe lung and liver diseases. The partners receive a total of €1.1 million in funding under the transnational E-Rare-3 programme on rare diseases.

>> Continue >> download PDF

 

13.12.2018

LDC and the University of Duisburg-Essen receive EUR 905,000 for the development of new therapies for age-related blindness

The Lead Discovery Center GmbH (LDC) and the University of Duisburg-Essen (UDE) have received EUR 905,000 in funding from the state of North Rhine-Westphalia as part of its lead market competition, LifeSciences.NRW. Together with the LDC’s own financial contribution, this gives the partners a total of EUR 1.3 million with which to develop new drugs for the treatment of age-related macular degeneration (AMD).

>> Continue >> download PDF

 

19.09.2018

APEIRON Announces Collaboration with  Lead Discovery Center GmbH

APEIRON Biologics AG, an Austrian company focused on cancer immunotherapy, today announced a collaboration agreement with the Lead Discovery Center GmbH (LDC), a translational research organization established in 2008 by Max Planck Innovation, to develop novel immune checkpoint modulators. The two companies will perform drug discovery activities to optimize and develop novel small molecules addressing immune checkpoints, important gatekeepers in cancer immunity. All molecules deriving from this collaboration are proprietary to APEIRON and will strengthen APEIRON’s development pipeline.

>> Continue >> download PDF

 

21.06.2018

Grünenthal, Lead Discovery Center and Max Planck Society enter into a research collaboration on Charcot-Marie-Tooth 1A (CMT1A)

Grünenthal, Lead Discovery Center GmbH (LDC), Max-Planck Innovation and Max Planck Institute of Experimental Medicine (MPI-EM) have entered into a research collaboration to develop novel therapies for patients suffering from Charcot-Marie-Tooth 1A (CMT1A), an inherited neurological disorder.

>> Continue >> download PDF

 

02.05.2018

Eleven million euros for Dortmund alliance for the development of new lead compounds

Innovative network of eight partners for North Rhine-Westphalia

Drug Discovery Hub Dortmund (DDHD) is the name of the new initiative at the Zentrum für integrierte Wirkstoffforschung (ZIW) of the TU Dortmund University (TU), which got started on 1 April 2018. Scientists from eight institutions combine their manifold expertise to develop an infrastructure for drug discovery in North Rhine-Westphalia. In addition to the TU Dortmund, the Max-Planck-Institute for Molecular Physiology (MPI), the Leibniz Research Centre for Working Environment and Human Factors (IfADo), the Leibniz-Institut für Analytische Wissenschaften - ISAS - e.V., the Taros GmbH & Co. KG, the PROvendis GmbH, the BioMedizinZentrum Dortmund (BMZ), and the Lead Discovery Center GmbH (LDC) are participating.

>> Continue >> download PDF

 

23.04.2018

LDC: New branch for development of therapeutic antibodies in Munich

The Lead Discovery Center GmbH (LDC) has established a branch - LDC Biologics - in the Munich Biocluster. While the team in Dortmund focuses on chemical compounds (small molecules), in Munich the emphasis will be on the development of therapeutic antibodies.

>> Continue >> download PDF

 

11.07.2017

Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Announce Cancer Research Collaboration

Daiichi Sankyo, Max Planck Innovation and LDC have signed an agreement providing Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for the treatment of cancer to be discovered and developed at LDC.

>> Continue >> download PDF

 

11.04.2017

LDC and SOTIO Enter License and Collaboration Agreement for First-in-class Cancer Metabolism Program

The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH (MI) and SOTIO a.s. have signed a collaboration and license agreement providing SOTIO with exclusive rights to an oncology program addressing a novel target in tumor metabolism. It was discovered at the Max Planck Institute for Biology of Ageing and jointly advanced by the LDC and Max Planck scientists into drug discovery.

 

>> Continue >> download PDF

 

20.03.2017

Arix Bioscience plc, LDC and University of Leeds collaborate to develop novel therapeutics for metabolic diseases

First project from LDC's agreement with Arix

Arix Bioscience plc (LSE:ARIX), a global healthcare and life science company supporting medical innovation, has signed an agreement with the Lead Discovery Center, Max Planck Innovation, and the University of Leeds to develop new therapeutics for metabolic diseases based on the discoveries from these organisations.

>> Continue >> download PDF

>> click here

 

 

news & press

Response to the structural transformation of the pharma industry [German only]

Bert Klebl, Peter Nussbaumer and Matthias Stein-Gerlach; transkript | Special Issue Kapital & Börse May 2009

>> download PDF >> Transkript Online

 

Polishing Medical Rough Diamonds

Text: Marcus Anhäuser
Max Planck Society Magazine Special “Innovation” / 2009
Pages 47 – 53

>> download PDF >> Max Planck multimedial

 

Joint Initiative for Research and Innovation

 

>> Link